Follistatin 344

Follistatin 344 is the 344-amino-acid precursor of human follistatin, a secreted protein that the body uses to dial down a family of growth regulators that includes myostatin, the best-known natural brake on muscle growth ¹². It was first isolated in 1987 from ovarian tissue as a protein that suppresses follicle-stimulating hormone (FSH), and later research showed it binds and neutralizes activins A and B, myostatin, and GDF11 ¹³.

Today most interest is in muscle growth and body recomposition. Transgenic pigs carrying human follistatin-344 gained skeletal muscle while carrying less fat ⁴, and a gene-delivery study in nonhuman primates reported gains in muscle size and strength ⁵. Human evidence remains limited to observational biomarker work and one adverse-event case series; no FDA-approved follistatin 344 product exists, and many tested black-market vials did not contain follistatin at all ¹.

Myostatin normally binds muscle-cell receptors and tells the cell to hold back growth. Follistatin 344 intercepts myostatin in the fluid outside cells before that receptor interaction happens, which removes the inhibitory signal and lets muscle-building programs proceed ¹³. Structural studies show the protein presents a flexible binding surface that can also neutralize activins A and B and GDF11 ¹⁴.

The 344-amino-acid precursor is processed into shorter mature forms. The longer circulating form stays mostly in the bloodstream, while the short form attaches to cell surfaces through sugar chains ¹¹. Animal models support the anabolic effect: pigs expressing human follistatin-344 grew more muscle and less fat, and nonhuman-primate gene-delivery studies reported increased size and strength ⁴.

Beyond muscle, follistatin influences fat and vascular tissue. In hypertensive rats it reduced oxidative stress and promoted browning of fat around blood vessels, improving vessel relaxation ²³. Endogenous follistatin also rises sharply after exercise as a signal released from the liver ⁷.

Most efficacy data come from animal models, so they show whether the mechanism works rather than proving human outcomes.

Muscle and body composition

• Muscle growth: transgenic pigs and nonhuman-primate gene-delivery models show clear increases in skeletal muscle ⁴.
• Fat loss: transgenic follistatin-344 pigs carried less fat with a metabolically benign liver ⁴, and mouse models lacking follistatin plus FSTL3 showed more fat and worse glucose handling, suggesting the follistatin axis normally restrains adiposity ¹⁶.
• Vascular function: in hypertensive rats, eight weeks of follistatin restored vessel relaxation through reduced oxidative stress and AMPK-dependent browning of perivascular fat ²³.

Human biomarker signals

• A single exercise bout raises circulating follistatin roughly 7-fold, peaking about 3 hours into recovery ⁷.
• A 12-week trial in older women found resistance exercise plus essential amino acids produced the largest rise in the follistatin/myostatin ratio ⁹.
• A meta-analysis found no reliable difference in circulating follistatin between sarcopenic and non-sarcopenic older adults, a reminder that blood levels may not track muscle status well ²².

Harm and disease signals

• A retrospective case series linked high-dose follistatin-344 use to central serous chorioretinopathy, fluid under the retina that blurs central vision ³.
• Tumor studies show follistatin can support proliferation, immune evasion, and drug resistance, with poor-prognosis signals in prostate, head and neck, and liver cancer ¹⁸.
• In animal nerve-injury models, follistatin sustains neuropathic pain through IGF1R-ERK/AKT signaling ²¹.

No human clinical trial of injectable follistatin 344 has been published, and no validated human dose-response relationship exists ². The strongest efficacy data are animal gene-transfer models: a single intramuscular AAV delivery in nonhuman primates ⁵, and germline expression in transgenic pigs ⁴.

Community research patterns

Community-derived protocols describe two main shapes:

• Standard short cycle: 50-100 mcg daily by subcutaneous or intramuscular injection for 7-20 days, followed by washout periods of 8 weeks or more (community protocol).
• Weight-scaled variant: about 0.7-1.5 mcg/kg daily is sometimes reported, rounding to roughly 70-100 mcg for a 73 kg adult, but no human pharmacokinetic data validate these numbers (community protocol).

Timing

Endogenous follistatin follows a 24-hour rhythm with a morning peak around 11:50 AM ¹⁰, and exercise raises it about 7-fold ⁷. Community practice therefore often times dosing on training days and uses morning dosing to align with the endogenous peak (community protocol).

The only documented human exposure harm signal comes from a retrospective case series of high-dose users, where dose details were not reported ³.

Follistatin 344 is supplied as a lyophilized powder reconstituted before injection. Because it is a larger, disulfide-rich glycoprotein rather than a short peptide, gentle handling matters: researchers typically avoid shaking, vortexing, or foaming, and add diluent slowly down the vial wall before rolling to dissolve (community protocol).

Bacteriostatic water is the standard diluent for multi-day research use, while sterile water is acceptable for immediate single use (community protocol). Reconstituted solution should be kept refrigerated at 2-8°C and discarded within about 30 days; lyophilized powder is best held at -20°C for long-term storage (community protocol). Avoid repeated freeze-thaw cycles, which can promote aggregation.

Product quality is the main handling risk: tested black-market vials often failed identity testing, and follistatin-positive samples were His-tagged with high oligomer content ¹. Visual inspection cannot confirm identity, so third-party verification is recommended before use. The interactive calculator on this page handles dilution math.

There are no formal human drug-interaction trials with Follistatin 344 ². The available evidence comes from animal studies, observational biomarker data, and one small GLP-1 trial.

• Heparin: follistatin binds heparin directly, which influences its normal cell-surface localization ⁴⁰. The clinical significance of combining exogenous follistatin 344 with heparin or low-molecular-weight heparin is unknown.
• Blood pressure medications: follistatin lowered blood pressure and restored vessel relaxation in hypertensive rats, so additive blood-pressure lowering is plausible but unstudied in humans ²³.
• Corticosteroids: steroid use independently raises central serous chorioretinopathy risk, the same retinal condition reported with high-dose follistatin-344 ³; combined exposure may compound retinal risk.
• GLP-1 receptor agonists: a 35-day liraglutide secondary analysis found no meaningful change in the myostatin-activin-follistatin-IGF-1 axis, suggesting no direct pharmacodynamic conflict ⁴⁵.
• Blood sugar medications: because follistatin tone affects glucose handling in animal models and circulating follistatin tracks glycemic control, glucose monitoring is emphasized in research discussions ¹⁶.
• Thyroid hormones: experimentally induced hyperthyroidism reduced muscle follistatin mRNA in mice without changing muscle mass ⁴⁴.
• Cancer treatments: because follistatin is implicated in tumor proliferation and drug resistance across solid tumors, researchers caution against combining with anticancer therapy ¹⁸.

Other myostatin inhibitors target the same ligand set and are considered redundant. Growth-hormone secretagogues and repair peptides are common community stacks without direct supporting interaction data (community protocol).

No published study establishes that Follistatin 344 produces classic receptor desensitization or tolerance. Cycling practices in the community are driven by the absence of human safety data, product-integrity problems, and concern about sustained myostatin blockade ¹.

Community-derived cycles typically run 7-20 days at 50-100 mcg daily, followed by washout periods of 8 weeks or more (community protocol). The animal evidence used for muscle growth comes from continuous transgenic expression or single-dose gene delivery, which does not model repeated peptide cycles ⁴.

Researchers point to several reasons pulsed treatment is favored over continuous exposure:

• Mass without function: follistatin overexpression added to exercise did not rescue motor-unit loss or neuromuscular transmission beyond exercise alone in mice, so muscle size gains do not guarantee functional strength ⁶.
• Tumor biology: sustained follistatin signaling is associated with progression and drug resistance in several solid cancers ¹⁸.
• Product quality: tested black-market vials frequently contain no follistatin or include His-tagged, oligomerized protein with unknown immune risk ¹.
• Ocular risk: high-dose use has been linked to retinal fluid accumulation ³.

Vision changes, plateaued response, new joint pain, hormonal symptoms, or injection-site reactions late in a cycle are the signals community guidance treats as reasons to stop and reassess (community protocol).

Follistatin 344 is frequently discussed as part of gray-market stacks, though no controlled trial evaluates these exact combinations.

• Injury recovery: community protocols commonly pair Follistatin 344 with BPC-157 or TB-500 for the combination of myostatin blockade and tissue-repair signaling (community protocol).
• GH secretagogues: CJC-1295, ipamorelin, sermorelin, and tesamorelin are common co-stacks (community protocol). Researchers flag caution because follistatin can engage IGF1R-ERK/AKT signaling in sensory neurons and sustain neuropathic pain in animal models ²¹.
• GLP-1 receptor agonists: stacking for lean-mass preservation during weight loss is common practice, and a 35-day liraglutide study showed a stable myostatin-activin-follistatin axis, so no direct conflict is expected ⁴⁵.
• Nutrition and training: a 12-week trial found resistance exercise plus twice-daily essential amino acids produced the largest rise in the follistatin/myostatin ratio and improved muscle mass in older women ⁹. Exercise itself raises circulating follistatin about 7-fold ⁷.
• AOD-9604: sometimes combined as a fat-loss complement to the anabolic signal, but the pairing is untested (community protocol).

Follistatin 344 has no approved pharmaceutical formulation in the United States or any other jurisdiction documented in the reviewed literature ¹. It is sold through unregulated gray-market channels, and no human efficacy trial has been completed ².

The compound is not scheduled as a controlled substance, but it is not an approved drug and does not appear on the FDA bulk-drug list used for standard pharmacy compounding. More practically, enforcement-grade testing has confirmed a chaotic supply: only 9 of 17 tested vials contained follistatin, and all positive samples were His-tagged with high oligomer content ¹.

In sport, follistatin is prohibited at all times under WADA class S4 as a hormone and metabolic modulator ¹. A validated urine test can detect the His-tagged black-market protein down to about 0.1 ng/mL, making anti-doping detection feasible ¹. Sports-medicine reviews classify it among unapproved peptides with scarce human safety data and potential for serious harm ².

No controlled human safety trial of injectable follistatin 344 exists, so the safety picture is built from case data, animal work, and product testing ².

• Retinal fluid: the most clearly documented human harm is central serous chorioretinopathy, a buildup of fluid under the retina causing blurred or distorted central vision. A retrospective case series linked it to high-dose follistatin-344 ³.
• Supply risk: in one forensic survey, only 9 of 17 black-market vials actually contained follistatin; some contained other growth peptides, and all positive vials were His-tagged and heavily oligomerized ¹. This creates misattributed side effects, immune-reaction risk, and unknown dosing.
• Cancer biology: follistatin is implicated in proliferation, immune evasion, and drug resistance across solid tumors, with high tumor follistatin predicting poor outcomes in prostate, head and neck, and liver cancer research ¹⁸.
• Pain signaling: follistatin sustains neuropathic pain pathways through IGF1R-ERK/AKT signaling in animal nerve-injury models, and reviews propose it as a pain target ²¹.
• Reproductive effects: follistatin overexpression caused reproductive defects in transgenic mice, and male mice lacking the short form had reduced reproductive-tract weight with elevated activins ³³.
• Metabolic and vascular signals: higher circulating follistatin is associated with vascular calcification in dialysis patients ³⁸, and fructose combined with follistatin worsened acute fatty liver disease in an animal model of hepatic insulin resistance ³⁶.

Because of these uncertainties, sports-medicine reviews describe scarce rigorous human safety data and potential for serious harm ².